Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07466251 (PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke), which is not on this map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07466251 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke (PISTIAS-3): a Randomized, Double-blind, Placebo-controlled Trial
TypeinterventionalSponsorPeking Union Medical College HospitalRan2026 to 2029Enrolled1,212ConditionsAcute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic PlaqueArmsRecaticimab plus standard therapy, Recaticimab's placebo in combination with standard therapy
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Xinzhi HuDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID 0009-0009-6304-5090
Yiyang LiuDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID 0009-0007-1395-7265
Weizhuang YuanDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID 0000-0002-3152-497X
Zongmuyu ZhangDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID 0000-0003-0206-2523
Shun LiDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID 0000-0003-2699-2784
Anqi ChengDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID 0009-0009-2702-0590
Qiuyu YuDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID 0009-0006-1294-4334
Haoyao GuoDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID 0009-0007-0785-7399
Yinxi ZouDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Mingli LiDepartment of Radiology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID 0000-0001-8456-0686
Caiyan LiuDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Yan XuDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID 0000-0003-3618-8271
Weihai XuDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID 0000-0003-3874-2598
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundWe aimed to investigate the effects of evolocumab, a proprotein convertase subtilisin/kexin type-9 inhibitor for intensive lipid-lowering, on intracranial atherosclerotic stenosis.
methodsFrom a prospectively established high-resolution magnetic resonance imaging database, consecutive patients with intracranial atherosclerotic stenosis (≥50%) with 2 detections of high-resolution magnetic resonance imaging over 6 months were included in this retrospective analysis. Eligible patients were grouped by treatment: evolocumab add-on (evolocumab
conclusionsEvolocumab add-on therapy over 6 months was associated with intracranial atherosclerotic plaque regression compared with statin therapy alone. However, given the retrospective design and potential between-group differences, these findings require further confirmation in prospective randomized controlled studies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.